Kairos Pharma, Ltd. (KAPA) Cash Flow Statement
Where KAPA’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$3.4M
- Capital expenditures
- $0
- Free cash flow
- −$3.4M
- Returned to shareholders
- —
- Change in cash
- $3.2M cash at year-end $4.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
KAPA operating cash flow, capex and free cash flow
KAPA cash flow trends, 2020–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$38,5352020 | −$3.4M2025 | — | |
| Capital expenditures | $52020 | $02025 | −100.0% | |
| Free cash flow | −$38,5352020 | −$3.4M2025 | — | |
| Stock-based compensation | $800,0002020 | $218,0002024 | −27.7%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
KAPA cash flow by activity
KAPA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
KAPA cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Operating activities | ||||||
| Net income | −$5.4M | −$2.6M | −$1.8M | −$1.1M | −$2.1M | −$1.1M |
| Depreciation & amortization | $160,000 | $160,000 | $160,000 | $160,000 | $98,000 | $0 |
| Stock-based compensation | — | $218,000 | $913,000 | $0 | $300,000 | $800,000 |
| Change in working capital | −$806,000 | −$2.0M | $764,000 | $129,000 | $1.2M | $212,818 |
| Other non-cash items | $2.7M | $254,000 | $56,000 | $408,000 | $144,000 | $0 |
| Cash from operating activities | −$3.4M | −$4.0M | $81,000 | −$353,000 | −$412,000 | −$38,535 |
| Investing activities | ||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | −$5 |
| Investments (net) | — | — | — | $0 | −$109,000 | $0 |
| Acquisitions & other investing | — | — | — | — | $0 | — |
| Cash from investing activities | — | — | — | — | −$109,000 | — |
| Financing activities | ||||||
| Net borrowing (repayment) | $0 | $0 | $0 | $895,000 | $330,000 | — |
| Shares issued | $0 | $5.5M | $0 | $0 | $250,000 | $0 |
| Other financing | $6.7M | −$390,000 | −$425,000 | −$178,000 | $0 | $37,000 |
| Cash from financing activities | $6.7M | $5.1M | −$425,000 | $717,000 | $580,000 | $37,000 |
| Summary | ||||||
| Net change in cash | $3.2M | $1.2M | −$344,000 | $364,000 | $59,000 | −$1,535 |
| Cash at end of period | $4.5M | $1.3M | $93,000 | $437,000 | $73,000 | $14,308 |
| Free cash flow | −$3.4M | −$4.0M | $81,000 | −$353,000 | −$412,000 | −$38,535 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$1.4M | −$1.7M | −$1.4M | −$1.4M | −$1.4M | −$1.3M | −$980,000 | −$1.0M | −$253,000 | −$323,000 | −$1.1M | −$312,000 |
| Depreciation & amortization | $22,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 | $40,000 |
| Stock-based compensation | $259,000 | — | −$76,000 | −$76,000 | — | $76,000 | — | — | — | — | — | — |
| Change in working capital | $73,000 | $99,000 | −$230,000 | −$210,000 | −$798,000 | $432,000 | −$610,000 | −$1.7M | $26,000 | $299,000 | $205,000 | $353,000 |
| Other non-cash items | $22,000 | $479,000 | $547,000 | $806,000 | $1.4M | $0 | −$253,000 | $685,999 | $19,000 | $20,000 | $939,000 | $10,000 |
| Cash from operating activities | −$1.0M | −$1.0M | −$1.1M | −$838,000 | −$805,000 | −$714,000 | −$1.8M | −$2.0M | −$168,000 | $36,000 | $66,000 | $91,000 |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | $0 | −$838,000 | −$838,000 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | $0 | $0 | — | — | −$142,000 | $40,000 | — | — | — | — |
| Shares issued | $7,000 | $385,000 | $0 | $0 | $223,000 | $0 | $0 | $5.5M | $0 | $0 | $0 | $0 |
| Other financing | −$44,000 | −$165,000 | $0 | $3.4M | $0 | $3.1M | $0 | −$348,000 | $149,000 | −$89,000 | −$72,000 | −$224,000 |
| Cash from financing activities | −$37,000 | $220,000 | $0 | $3.4M | $223,000 | $3.1M | −$142,000 | $5.2M | $149,000 | −$89,000 | −$72,000 | −$224,000 |
| Summary | ||||||||||||
| Net change in cash | −$1.0M | −$816,000 | −$1.1M | $2.5M | −$582,000 | $2.3M | −$1.9M | $3.2M | −$19,000 | −$53,000 | −$6,000 | −$133,000 |
| Cash at end of period | $2.6M | $3.7M | $4.5M | $5.6M | $3.0M | $3.6M | $1.3M | $3.2M | $21,000 | $40,000 | $93,000 | $99,000 |
| Free cash flow | −$1.0M | −$1.0M | −$1.1M | −$838,000 | −$805,000 | −$714,000 | −$1.8M | −$2.0M | −$168,000 | $36,000 | $66,000 | $91,000 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
KAPA cash generation
In fiscal 2025 (ended December 31, 2025), Kairos Pharma generated -$3.4 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$3.4 million. Cash and equivalents rose by $3.2 million over the year.
Related: KAPA income statement, KAPA balance sheet. See the KAPA stock overview for the latest quote and news.
KAPA cash flow FAQ
What is Kairos Pharma's free cash flow?
Kairos Pharma's free cash flow was -$3.4 million in fiscal 2025: -$3.4 million of operating cash flow minus $0 of capital expenditures It was -$4.0 million a year earlier..
How much cash does Kairos Pharma generate from operations?
Kairos Pharma generated -$3.4 million of cash from operating activities in fiscal 2025.